Baidu
map

Allergy Asthma Clin Immunol:患有或不患有过敏性哮喘的常年性过敏性鼻炎对睡眠、工作和活动水平的影响

2019-12-27 AlexYang MedSci原创

过敏性呼吸疾病,比如过敏性鼻炎(AR)和过敏性哮喘(AA)是常见的情况,能够对睡眠和白天的活动产生影响。然而,上述影响的意义仍旧不清楚,尤其是在常年过敏性患者中。最近,有研究人员调查了常年过敏对睡眠、日常活动和效率的影响情况。研究总共包括了511名常年AR患者(47.4%的患者同时患有季节性过敏),且都完成了调查问卷。大多数受试者(77.5%)具有医生诊断的AR;46.4%的患者被同时诊断为AR和

过敏性呼吸疾病,比如过敏性鼻炎(AR)和过敏性哮喘(AA)是常见的情况,能够对睡眠和白天的活动产生影响。然而,上述影响的意义仍旧不清楚,尤其是在常年过敏性患者中。最近,有研究人员调查了常年过敏对睡眠、日常活动和效率的影响情况。

研究总共包括了511名常年AR患者(47.4%的患者同时患有季节性过敏),且都完成了调查问卷。大多数受试者(77.5%)具有医生诊断的AR;46.4%的患者被同时诊断为AR和AA。大多数受试者(65.2%)报道对屋尘螨敏感。在所有的受试者中,66.0%的报道具有睡眠问题。患有睡眠问题的受试者每天晚上醒来的次数均值为3.8,92%的需要花费超过15分钟的时间再次入睡(22.2%的患者超过60分钟)。关于在晚上醒来分析发现,40.8%的受试者尝试再次入睡,69.2%的受试者由于困乏在早上醒来有困难。由于睡眠问题导致白天工作受影响的受试者占比85.5-95%。工作和活动受影响的比例分别占比53.3%和47.1%。睡眠问题在诊断为AA和AR的患者要比单独AR更加频繁和更加严重,并且对日常生活影响更大(47.0% vs 33.3%),包括了以及工作和活动(62.0% 和54.9% vs 39.3%和35.2%)。在所有的受试者中,20.5%的受试者在接受调查时接受AIT,其中36.4%的受试者报道由于过敏原治疗睡眠问题得到了一定程度或者更大程度的改善。

最后,研究人员指出,在常年性AR患者中,睡眠问题是常见的并且影响日常活动,并且在AR和AA患者中比单独AR患者更加严重。

原始出处:

Romano MR, James S, Farrington E et al. The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level. Allergy Asthma Clin Immunol. 06 Dec 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047207, encodeId=dcab204e20736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 03 02:47:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977149, encodeId=35b019e7149e8, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Feb 22 23:47:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712246, encodeId=22a51e12246cd, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Nov 05 21:47:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329319, encodeId=d0c31329319a1, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499957, encodeId=1df9149995e4a, content=<a href='/topic/show?id=fcf094038bb' target=_blank style='color:#2F92EE;'>#过敏性哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94038, encryptionId=fcf094038bb, topicName=过敏性哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a19396608, createdName=wodejia-dayu, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047207, encodeId=dcab204e20736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 03 02:47:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977149, encodeId=35b019e7149e8, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Feb 22 23:47:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712246, encodeId=22a51e12246cd, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Nov 05 21:47:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329319, encodeId=d0c31329319a1, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499957, encodeId=1df9149995e4a, content=<a href='/topic/show?id=fcf094038bb' target=_blank style='color:#2F92EE;'>#过敏性哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94038, encryptionId=fcf094038bb, topicName=过敏性哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a19396608, createdName=wodejia-dayu, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2020-02-22 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047207, encodeId=dcab204e20736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 03 02:47:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977149, encodeId=35b019e7149e8, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Feb 22 23:47:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712246, encodeId=22a51e12246cd, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Nov 05 21:47:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329319, encodeId=d0c31329319a1, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499957, encodeId=1df9149995e4a, content=<a href='/topic/show?id=fcf094038bb' target=_blank style='color:#2F92EE;'>#过敏性哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94038, encryptionId=fcf094038bb, topicName=过敏性哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a19396608, createdName=wodejia-dayu, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047207, encodeId=dcab204e20736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 03 02:47:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977149, encodeId=35b019e7149e8, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Feb 22 23:47:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712246, encodeId=22a51e12246cd, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Nov 05 21:47:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329319, encodeId=d0c31329319a1, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499957, encodeId=1df9149995e4a, content=<a href='/topic/show?id=fcf094038bb' target=_blank style='color:#2F92EE;'>#过敏性哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94038, encryptionId=fcf094038bb, topicName=过敏性哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a19396608, createdName=wodejia-dayu, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2019-12-29 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047207, encodeId=dcab204e20736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 03 02:47:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977149, encodeId=35b019e7149e8, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Feb 22 23:47:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712246, encodeId=22a51e12246cd, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Nov 05 21:47:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329319, encodeId=d0c31329319a1, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499957, encodeId=1df9149995e4a, content=<a href='/topic/show?id=fcf094038bb' target=_blank style='color:#2F92EE;'>#过敏性哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94038, encryptionId=fcf094038bb, topicName=过敏性哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a19396608, createdName=wodejia-dayu, createdTime=Sun Dec 29 04:47:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]

相关资讯

Nutrients:饮食中的ω-3脂肪酸能够抑制过敏性鼻炎

代谢和生物活性脂质调节因子的产生是饮食中的ω-3脂肪酸在调控过敏性炎症中发挥有益作用的关键过程。最近,有研究人员发现食用包含高水平亚麻酸(ALA)的亚麻籽油能够抑制过敏性鼻炎,具体机制是通过嗜酸性产生15-羟基二十碳五烯酸(15-HEPE)来实现抑制效果的,15-HEPE是一种二十碳五烯酸(EPA)代谢产物。在发展为过敏性鼻炎且嗜酸性细胞数据增加时,脂肪体分析阐释了15-HEPE在亚麻籽油喂食的小

Clin Transl Sci:过敏性鼻炎的敏感基因鉴定

作为一种世界范围内极度流行的疾病,过敏性鼻炎(AR)是一种鼻粘膜慢性炎症疾病。最近,有研究人员为了鉴定与AR易感基因相关的更加精细的分子机制,研究人员调查了AR患者中的差异表达基因(DEGs)。研究人员使用DEG表达和GSE19187临床数据库进行了加权基因共表达分析(WGCNA)。当与AR相关的模块筛选过后,研究人员将模块中的基因用于基因本体和KEGG途径富集分析,而在KEGG途径富集的基因认为

Life Sci:Tet2下调与过敏性鼻炎调控T细胞的Foxp3 TSDR超甲基化相关

Tet蛋白是5-甲基胞嘧啶氧化酶,并且对DNA甲基化和基因表达具有深刻的影响。最近,有研究人员调查了过敏性鼻炎(AR)调控T细胞(Treg)中Tet2的作用以及与Foxp3 DNA甲基化的相关性情况。研究人员利用流式细胞仪对AR患者的外周血淋巴细胞和OVA诱导小鼠的脾淋巴细胞进行了分离。研究人员发现,与对照相比,来源于AR患者的OVA诱导的小鼠的Treg细胞数目减少,Foxp3 mRNA和蛋白表达

BMC Pediatr:儿科中特异性疾病与贫血相关性研究

特应性疾病,比如过敏性皮肤炎、过敏性鼻炎和哮喘均是儿科患者中常见的炎症疾病。最近,有研究人员调查了儿科患者中是否这些特应性炎症疾病与贫血相关。研究是一个代表性的研究,数据来源于2016年韩国HIRA儿科数据库资料。研究总共包括了846718名儿科患者。其中,19594名(2.31%)诊断为缺铁性贫血(IDA)。包含协变量的逻辑回归分析阐释了特应性疾病与IDA之间存在相关性。其中,过敏性皮肤炎中ID

Indian J Otolaryngol Head Neck Surg:医生对过敏性鼻炎和治疗的看法

尽管过敏性鼻炎(AR)具有较高的患病率且对生活质量影响较大,但是该疾病仍旧是治疗不足。更多的是,AR与上呼吸道感染(URTI)之间的关系很少有探索。最近,有研究人员评估了医生对AR和RUTI的认识以及治疗实践情况。研究基于调查问卷,共电话访问了300名医生,其中会诊医师(CP): 33%,普通医师(GP): 32%,ENT外科医生:16%,儿科医生:11%,过敏症专家:8%。1个月中,CPs(33

J Asthma:FeNO和MMEF在预测患有或者不患有过敏性鼻炎慢性咳嗽患者中的咳嗽变异性哮喘中的诊断价值分析

最近,有研究人员评估了呼出气中一氧化氮浓度(FeNO)和最大中段呼气流速(MMEF)在患有或者不患有过敏性鼻炎慢性咳嗽患者中区分咳嗽变异性哮喘(CVA)的诊断价值情况。研究总共包括了328名慢性咳嗽患者,且经历了呼吸量测试和FeNO测试。研究人员根据CVA诊断标准将患者分成了两个小组,CVA组(n=125)和NCVA(n=203)组。研究发现,FeNO和MMEF从慢性咳嗽中区分CVA的最优FeNO

Baidu
map
Baidu
map
Baidu
map